News & Media

Subscribe to the BAM Newsletter

Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.


DispersinB® Topical Wound Gel Manufacturing Completed

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that BioVectra has successfully completed the manufacturing of DispersinB® Topical Wound Gel un


Medicure Announces Private Placement

Medicure Inc. ("Medicure" or the "Company") (TSX: MPH) announces its plan to raise up to $3.0 million to improve its financial position through a non-brokered private placement of common shares (the "Offering") at a price of $0.05 per common share.


Ray of Hope for Cancer Patients

The technology, called the AutoLITT System, uses an MRI-guided laser probe, passed through a hole in the skull about the size of a dime, to deliver laser interstitial thermal therapy (LITT) to heat and coagulate the tumour from the inside.


Kane Biotech Announces Private Placement Offering

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms (the “Company”), today announces a non-brokered private placement offering (the “Offering”) for gross proceeds of up


Scientists Learning To Target Bacteria Where They Live

In the arms race between humans and bacteria, the ability to form "biofilms" -- large aggregations of microbes embedded in a slimy matrix -- has been one of the weapons the organisms use to defeat the immune system, antibiotic drugs and other threats. But


MGI Pharma vet takes DiaMedica reins

Reggie Bowerman saw the doors close at MGI Pharma Inc.’s former headquarters late last year. Now, he’s aiming to open some new doors in biotech for a Canadian startup setting up shop in Minnesota.


Miraculins Announces Amendment to Private Placement Offering

Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces today an amendment to the terms of its private placement offering (the "Offering") announced on Novemb